SleepRes, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kricket PAP device, powered by Kairos Positive Airway Pressure (KPAP)™ for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. The SleepRes PAP system is intended for home, hospital/institutional, […]
Central Sleep Apnea
Zoll Remedē System Trial Shows Promise for HF Patients with Central Sleep Apnea
ZOLL® has announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for heart failure (HF) patients with central sleep apnea (CSA). The analysis was performed post-hoc using a hierarchical endpoint comprised of mortality, HF hospitalization, and health status. The new analysis was […]
Five Year Study Confirms Efficacy of Central Sleep Apnea Therapy Device
ZOLL® Medical Corporation announced that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study. The data show sustained safety and efficacy of transvenous phrenic nerve stimulation for the treatment of moderate to severe central sleep apnea (CSA). The remedē® System, the only implantable device […]






